NCT04920981Completed
Atezolizumab Combined With Chemotherapy in Extensive Stage SCLC
Real World Effectiveness and Treatment Sequences in Patients With Extensive Stage SCLC Who Received Atezolizumab Combined With Chemotherapy as Part of the French Early Access Program (ATU).
Source: ClinicalTrials.gov · Last updated 7 Nov 2024
Brief summary (registry, in English)
CLINATEZO cohort will evaluate overall survival, real world progression-free survival, best response and duration of treatment in patients with advanced, metastatic Small Cell Lung Cancer (SCLC) who received atezolizumab combined with chemotherapy part of the French Early Access Program (ATU). Subsequent treatments (treatment delivered immediately after treatment with atezolizumab and chemotherapy) will be recorded. Those outcomes will be correlated to clinical, pathological, and radiological characteristics of patients.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 518 (actual)
- First submitted
- 28 Apr 2021
- Start date
- 2 Feb 2021
- Primary completion date
- 24 Nov 2021
- Lead sponsor
- Intergroupe Francophone de Cancerologie Thoracique
- Diseases
- Lung cancer
- NCT number
- NCT04920981
What you commit to
- Study type: Observational
- Participants enrolled: 518
- From 2 Feb 2021 to the primary completion date, 24 Nov 2021
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients enrolled in a clinical trial assessing treatment with a combination of atezolizumab and chemotherapy. (ATU was granted to patients unable to meet eligibility criteria for on-going recruiting trials, unable to participate to other clinical trials, or because other medical interventions were not considered appropriate or acceptable).
- Patients who were included in the French Early Access Program (ATU program) but did not receive any atezolizumab and chemotherapy treatment.
Who the study is looking for
- Patients with histologically or cytologically confirmed extensive stage Small Cell Lung Cancer at time of initiation of treatment with atezolizumab and chemotherapy.
- Patients who were informed about the study and accepted for their data to be collected.
- Patients who received at least one dose of treatment with atezolizumab and chemotherapy as part of the French Early Access Program (ATU program) and have been accepted within this ATU program
- Selection period spans from May 6th 2019 until January 31st 2020 for initiation of treatment with atezolizumab and chemotherapy.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chalon-sur-Saône - CH Coordinator of this site? Confirm its status | Chalon-sur-Saône | France | Unknown status |
| Paris - Institut Curie Coordinator of this site? Confirm its status | Paris | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.